#USA #Boston #gene therapy #Nanoscope Therapeutics #Retina

Nanoscope Therapeutics to Showcase Innovations at ASGCT 2026

Nanoscope Therapeutics Inc. is gearing up to make significant contributions at the upcoming 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT 2026) held in Boston from May 11 to May 15, 2026. This biotech powerhouse is devoted to developing and commercializing cutting-edge gene therapies aimed at restoring the vision of individuals suffering from retinal degenerative diseases.

The Groundbreaking MCO-010 Therapy

At the heart of Nanoscope's presentation will be the MCO-010 optogenetic therapy, which stands as a beacon of hope for patients with conditions such as advanced retinitis pigmentosa (RP). MCO-010 is noted not only for being the most advanced program within the multi-characteristic opsin (MCO) platform but also for being the first mutation-agnostic therapy capable of restoring vision through a straightforward, one-time intravitreal injection.

During the conference, Dr. Samarendra Mohanty, co-founder and President of Nanoscope, expressed excitement over sharing the significant clinical observations illustrating the potential benefits this treatment may hold for patients. The gathering will feature detailed insights about the therapeutic effects seen in patients with RP and Stargardt disease, further fueling Nanoscope's optimism as they conclude their Biologics License Application (BLA) submission process to the FDA for MCO-010.

Key Presentations to Look Forward To

Nanoscope will be hosting a series of pivotal presentations during the event, which include:

• - Bilateral Improvement in Vision: Dr. Vinit Mahajan will delve into findings related to bilateral functional enhancement in patients post-administration of the MCO-010 therapy, with discussions scheduled for May 12, from 4:00 PM to 4:15 PM ET. This segment aims to highlight quantitative observations from both nonclinical studies and clinical trials involving RP and Stargardt disease patients.

• - Mechanisms Behind Color Vision Enhancement: Another noteworthy session on May 15, led by Dr. Samarendra Mohanty from 4:15 PM to 4:30 PM ET, will address how the MCO-010 treatment improves color discrimination in patients with outer retinal degeneration.

In addition to these podium presentations, Nanoscope will also display posters outlining key findings from their research efforts. Among these, Dr. Amir Singh will discuss innovative techniques for quantifying replication-competent AAV in the manufacturing process of gene therapies on May 13. Meanwhile, Dr. Ananta Ayyagari will provide insights on the challenges faced in Chemistry, Manufacturing, and Controls (CMC) for gene therapy regulatory approvals during a similar poster session.

About the MCO Platform: A Vision Restoration Revolution

The MCO platform is a groundbreaking, one-time a therapy offered in a clinical setting, designed specifically for patients grappling with the loss of their photoreceptors due to degenerative diseases like RP, Stargardt disease, and geographic atrophy (GA). By enhancing the sensitivity of particular retinal cells to light, MCO enables residual visual pathways to function optimally—ensuring accessibility to patients without the need for invasive tests or frequent treatments.

Nanoscope’s Vision for the Future

As Nanoscope Therapeutics advances its innovative solutions for reversing blindness and ensuring retinal health, positive results from their RESTORE Phase 2b/3 clinical trial for RP have initiated a rolling BLA submission process with the FDA. If approved, the MCO-010 could redefine the standard of care for RP, provided as a simple in-office injection devoid of the necessity for genetic testing.

Building upon strong findings from their STARLIGHT Phase 2 clinical trial concerning Stargardt disease, Nanoscope also plans to launch a Phase 3 registration study in 2026, furthering their mission to provide transformative care options to patients suffering from these debilitating conditions.

Conclusion

Nanoscope Therapeutics stands at the forefront of vision restoration science, and the contributions at ASGCT 2026 will certainly pave the way for more profound advancements in the field. With significant hopes around MCO-010, it’s a time of excitement for those involved in retinal research as well as for countless patients whose lives could be transformed by these innovative therapies.